Spyre Therapeutics, Inc. (NASDAQ:SYRE) Financings

Spyre Therapeutics, Inc.

Financings

RaiseDate
Public offering of common stock
Closed: US$400M raised · US$85 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Leerink Partners (co-lead), Stifel (co-lead), LifeSci Capital
Use of proceeds: To fund a pivotal program in hidradenitis suppurativa with SPY072, its TL1A monotherapy
Nov 3, 2026
At-the-market programme of common stock
Tranche closed: US$18M raised
Nov 3, 2026
Public offering of common stock
Made bigger: about US$403M · US$62 a share · Jefferies LLC +4
Dealers: Jefferies LLC (co-lead), Goldman Sachs & Co. LLC (co-lead), Evercore ISI (co-lead), Guggenheim Securities, LLC (co-lead), LifeSci Capital LLC
Apr 14, 2026
Public offering of common stock
Closed: US$316.2M raised · US$18.5 a share · Jefferies LLC +4
Dealers: Jefferies LLC (co-lead), TD Securities (USA) LLC (co-lead), Leerink Partners LLC (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), Wedbush Securities Inc.
Oct 15, 2025

Read by 6ix AI from the company's releases